Literature DB >> 17900408

Effects of melatonin and rilmazafone on nocturia in the elderly.

K Sugaya1, S Nishijima, M Miyazato, K Kadekawa, Y Ogawa.   

Abstract

We compared the effects of melatonin, an antioxidant and sleep inducer in humans, and rilmazafone hydrochloride, a hypnotic, in elderly patients with nocturia. Patients received either melatonin (2 mg/day; n = 20) or rilmazafone (2 mg/day; n = 22) for 4 weeks. There were no significant differences in the mean age, the quality of life (QoL) score and the serum melatonin levels between the two groups at baseline. After 4 weeks' treatment, the number of nocturnal urinations was significantly decreased and the QoL score was significantly improved in both groups. There was no significant difference between the patient-reported effectiveness ratings between the two groups. The serum melatonin level was significantly increased in the melatonin-treated group, but it remained unchanged in the rilmazafone-treated group. Melatonin and rilmazafone were equally effective for nocturia in the elderly. We recommend that the problems of sleep disturbance should be considered when choosing a therapy for nocturia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900408     DOI: 10.1177/147323000703500513

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Melatonin inhibits muscular-mucosal stretch-sensitive bladder afferents via the MT2 receptors.

Authors:  Stewart Ramsay; Vladimir Zagorodnyuk
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

2.  Self-Assessed Benefits of a Prostate Health Formulation on Nocturia in Healthy Males With Mild Lower Urinary Tract Symptoms: An Open Label Study.

Authors:  Steven P Hirsh; Marianne Pons; Steven V Joyal; Andrew G Swick
Journal:  Glob Adv Health Med       Date:  2020-11-27

Review 3.  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.

Authors:  Esmée M S Vural; Barbara C van Munster; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 4.  Nocturia: aetiology and treatment in adults.

Authors:  Hasan Dani; Ashanda Esdaille; Jeffrey P Weiss
Journal:  Nat Rev Urol       Date:  2016-07-26       Impact factor: 14.432

Review 5.  Age-Related Sleep Disruption and Reduction in the Circadian Rhythm of Urine Output: Contribution to Nocturia?

Authors:  Jeanne F Duffy; Karine Scheuermaier; Kevin R Loughlin
Journal:  Curr Aging Sci       Date:  2016

6.  A novel pathway underlying the inhibitory effects of melatonin on isolated rat urinary bladder contraction.

Authors:  June Hyun Han; In Ho Chang; Soon Chul Myung; Moo Yeol Lee; Won Yong Kim; Seo Yeon Lee; Shin Young Lee; Seung Wook Lee; Kyung Do Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-02-28       Impact factor: 2.016

7.  Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).

Authors:  D Delgado; L Canham; N Cotterill; D Cottrell; M J Drake; K Inglis; D Owen; P White
Journal:  BMC Neurol       Date:  2017-03-27       Impact factor: 2.474

Review 8.  Pharmacotherapy for Nocturia.

Authors:  Karl-Erik Andersson; Philip Van Kerrebroeck
Journal:  Curr Urol Rep       Date:  2018-02-09       Impact factor: 3.092

Review 9.  Dietary considerations in the evaluation and management of nocturia.

Authors:  Upeksha S Alwis; Thomas F Monaghan; Rebecca Haddad; Jeffrey P Weiss; Saskia Roggeman; Erik Van Laecke; Johan Vande Walle; Alan J Wein; Karel Everaert
Journal:  F1000Res       Date:  2020-03-05

10.  Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).

Authors:  Marcus J Drake; Luke Canham; Nikki Cotterill; Debbie Delgado; Jenny Homewood; Kirsty Inglis; Lyndsey Johnson; Mary C Kisanga; Denise Owen; Paul White; David Cottrell
Journal:  BMC Neurol       Date:  2018-08-06       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.